Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Gonzalo Villapalos García"'
Autor:
Emilia Roy-Vallejo, Sara Fernández De Córdoba-Oñate, Pablo Delgado-Wicke, Ana Triguero-Martínez, Nuria Montes, Rosa Carracedo-Rodríguez, Nelly Zurita-Cruz, Ana Marcos-Jiménez, Amalia Lamana, José María Galván-Román, Gonzalo Villapalos García, Pablo Zubiaur, Marianela Ciudad, Laura Rabes, Marta Sanz, Carlos Rodríguez, Almudena Villa, Jesús Álvarez Rodríguez, Celeste Marcos, Julia Hernando, Paula Díaz-Fernández, Francisco Abad, Ignacio de los Santos, Diego A. Rodríguez Serrano, Rosario García-Vicuña, Carmen Suárez Fernández, Rosa P. Gomariz, Cecilia Muñoz-Calleja, Elena Fernández-Ruiz, Isidoro González-Álvaro, Laura Cardeñoso, the PREDINMUN-COVID Group
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionSARS-CoV-2 viral load has been related to COVID-19 severity. The main aim of this study was to evaluate the relationship between SARS-CoV-2 viremia and SNPs in genes previously studied by our group as predictors of COVID-19 severity.Mater
Externí odkaz:
https://doaj.org/article/8ca2939964894199a76694e0185eb3b7
Autor:
Pablo Delgado-Wicke, Sara Fernández de Córdoba-Oñate, Emilia Roy-Vallejo, Estíbaliz Alegría-Carrasco, Diego A. Rodríguez-Serrano, Amalia Lamana, Nuria Montes, Ana Nicolao-Gómez, Rosa Carracedo-Rodríguez, Ana Marcos-Jiménez, Paula Díaz-Fernández, José M. Galván-Román, Laura Rabes-Rodríguez, Marta Sanz-Alba, Jesús Álvarez-Rodríguez, Almudena Villa-Martí, Carlos Rodríguez-Franco, Gonzalo Villapalos-García, Pablo Zubiaur, Francisco Abad-Santos, Ignacio de los Santos, Rosa P. Gomariz, Rosario García-Vicuña, Cecilia Muñoz-Calleja, Isidoro González-Álvaro, Elena Fernández-Ruiz, PREDINMUN-COVID Group
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The characteristics of the host are crucial in the final outcome of COVID-19. Herein, the influence of genetic and clinical variants in COVID-19 severity was investigated in a total of 1350 patients. Twenty-one single nucleotide polymorphism
Externí odkaz:
https://doaj.org/article/0d1fc16c70a649cfaebb526fed6a8fbd
Autor:
Ana Casajús, Pablo Zubiaur, Enrique Alday, Paula Soria‐Chacartegui, Miriam Saiz‐Rodríguez, Lara Gutierrez, Catalina Aragonés, Diana Campodónico, Antía Gómez‐Fernández, Marcos Navares‐Gómez, Gonzalo Villapalos‐García, Gina Mejía‐Abril, Dolores Ochoa, Francisco Abad‐Santos
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract Tramadol is an important minor opioid prescribed for pain management. In this study, we analyzed the well‐known impact of CYP2D6 genetic variation and 60 additional variants in eight candidate genes (i.e., ABCG2, SLCO1B1, CYP2D6, CYP2B6, C
Externí odkaz:
https://doaj.org/article/4726d4d4aebd482ea7adce76f4619f4a
Autor:
Paula Soria-Chacartegui, Gonzalo Villapalos-García, Luis A. López-Fernández, Marcos Navares-Gómez, Gina Mejía-Abril, Francisco Abad-Santos, Pablo Zubiaur
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2036 (2021)
Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity. Polymorphism of the dihydropyrimidine dehydrogenase (DPYD) gene may reduce DPD function, the main enzyme responsible for the metabolism of fluoropyrimidines. This
Externí odkaz:
https://doaj.org/article/e8ac976655a34f4bbe8c9cf51e102763
Autor:
Pablo Zubiaur, Paula Fernández-Campos, Marcos Navares-Gómez, Paula Soria-Chacartegui, Gonzalo Villapalos-García, Manuel Román, Gina Mejía-Abril, Dolores Ochoa, Francisco Abad-Santos
Publikováno v:
Pharmaceutics, Vol 13, Iss 10, p 1573 (2021)
Quetiapine is an atypical antipsychotic widely used for the treatment of schizophrenia and the depressive episodes of bipolar disorder. The aim of this work was to investigate the effect of variants in relevant pharmacogenes in the pharmacokinetics o
Externí odkaz:
https://doaj.org/article/822671eacdeb4c6190958df7aa9f3269
Autor:
Paula Soria-Chacartegui, Pablo Zubiaur, Dolores Ochoa, Gonzalo Villapalos-García, Manuel Román, Miriam Matas, Laura Figueiredo-Tor, Gina Mejía-Abril, Sofía Calleja, Alejandro de Miguel, Marcos Navares-Gómez, Samuel Martín-Vilchez, Francisco Abad-Santos
Publikováno v:
Pharmaceutics
Volume 15
Issue 2
Pages: 404
Volume 15
Issue 2
Pages: 404
Amlodipine is an antihypertensive drug with unknown pharmacogenetic biomarkers. This research is a candidate gene study that looked for associations between amlodipine pharmacokinetics and safety and pharmacogenes. Pharmacokinetic and safety data wer
Autor:
Ana Marcos-Jiménez, Daniela Claudino Carvoeiro, Nora Ruef, Carlos Cuesta-Mateos, Emilia Roy-Vallejo, Valle Gómez-García de Soria, Claudio Laganá, Lourdes del Campo, Pablo Zubiaur, Gonzalo Villapalos-García, Francisco Abad-Santos, Jens V. Stein, Cecilia Muñoz-Calleja
Publikováno v:
Blood advances.
The tyrosine kinase inhibitor dasatinib is approved for Philadelphia chromosome–positive leukemia, including chronic myeloid leukemia (CML). Although effective and well tolerated, patients typically exhibit a transient lymphocytosis after dasatinib
Autor:
Francisco Abad-Santos, Juan J Gordillo-Perdomo, Paula Soria-Chacartegui, Pablo Zubiaur, Gonzalo Villapalos-García
Publikováno v:
Pharmacogenomics. 22:939-958
Genetic polymorphism in olanzapine-metabolizing enzymes, transporters and drug targets is associated with alterations in safety and efficacy. The aim of this systematic review is to describe all clinically relevant pharmacogenetic information on olan
Autor:
Pablo Zubiaur, Miriam Matas, Samuel Martín-Vílchez, Paula Soria-Chacartegui, Gonzalo Villapalos-García, Laura Figueiredo-Tor, Sofía Calleja, Marcos Navares-Gómez, Alejandro de Miguel, Jesús Novalbos, Gina Mejía-Abril, Sergio Luquero-Bueno, Manuel Román, Dolores Ochoa, Francisco Abad-Santos
Publikováno v:
Pharmaceutics; Volume 14; Issue 10; Pages: 2001
Rasagiline is a selective and irreversible inhibitor of monoamine oxidase type B with neuroprotective effect, indicated for the management of Parkinson’s disease. The aim of this work was to evaluate the impact of seven CYP1A2 alleles and of 120 ad
Autor:
Diana María Campodónico, Pablo Zubiaur, Paula Soria‐Chacartegui, Ana Casajús, Gonzalo Villapalos‐García, Marcos Navares‐Gómez, Antía Gómez‐Fernández, Raúl Parra‐Garcés, Gina Mejía‐Abril, Manuel Román, Samuel Martín‐Vílchez, Dolores Ochoa, Francisco Abad‐Santos
Publikováno v:
Clinical and translational science. 15(11)
Cinitapride is a gastrointestinal prokinetic drug, prescribed for the treatment of functional dyspepsia, and as an adjuvant therapy for gastroesophageal reflux disease. In this study, we aimed to explore the impact of relevant variants in CYP3A4 and